TP53 and small cell lung carcinoma: TP53 rs1042522 (Arg72Pro) was associated with an increased risk of grade 3-4 neutropenia in recessive model (OR = 3.44; 95% CI: 1.302–9.111; p = 0.012) in 119 SCLC patients treated with cisplatin and etoposide (Wang et al., 2014).